MeCure Industries Plc, a pharmaceutical company in Nigeria, has reported a 45 percent increase in revenue, rising to N46.03 billion in 2024 from N31.76 billion in 2023, due to rising demand and increased sales.
This surge can be attributed to N25.2 billion in sales of acute medications, N10.2 billion in sales of OTC (over-the-counter) medications, and N5.1 billion in sales of supplement medications.
BusinessDay findings from the firm’s latest financial result reveal that despite the revenue boost, profitability took a hit with its after-tax profit falling to N2.32 billion from N2.91 billion.